Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention.
The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer.
The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States.
Leadership:
Bill Brodie, Chief Executive Officer
Robert T. Hamilton, CPA, Chief Financial Officer
Dragan Nebrigic, Ph.D., Chief Operating Officer
Ben Beckham, Chief Commercial Officer
Michael Donovan, M.D. Ph.D., Chief Clinical Officer
Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Kris Foss, Vice President, Regulatory, Quality & Clinical
Location: United States, Florida, Fort Lauderdale
Employees: 11-50
Phone: +1 305-728-5382
Total raised: $16M
Founded date: 2011
Investors 2
Date | Name | Website |
- | White Owl ... | whiteowlca... |
- | Florida In... | florida-in... |
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
11.07.2016 | Series B | $10.5M | - | vcnewsdail... |
24.02.2015 | Series B | $5.5M | - | vcnewsdail... |
Mentions in press and media 12
Date | Title | Description | Source |
09.09.2020 | Vigilant Biosciences Announces New Website Launch | FORT LAUDERDALE, Fla., Sept. 9, 2020 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant&qu... | prnewswire... |
31.01.2020 | Investors in the house at FVCC, and Florida startups were in... | Facebook Tweet Pin LinkedIn Email By Nancy Dahlberg Macro economic indicators may be signaling... | refreshmia... |
14.01.2020 | South Florida’s 2019 was a record-buster for VC. Who raised ... | Facebook Tweet Pin LinkedIn Email South Florida snagged $2.37 billion in venture capital in 201... | refreshmia... |
11.07.2016 | Vigilant Biosciences raises $10.5M in Series B round | The money will be used in commercialization efforts, especially to make the Fort Lauderdale, Florida... | medcitynew... |
11.07.2016 | Vigilant Biosciences Completes $5M Series B2 Financing | Vigilant Biosciences, Inc., a Ft. Lauderdale, FL-based developer of solutions that aid in the early ... | finsmes.co... |
11.07.2016 | Vigilant Biosciences Lands $5M Series B-2 | FORT LAUDERDALE, FL, Developer of solutions announced the successful completion of a $5 million ro... | vcnewsdail... |
02.03.2015 | Vigilant Biosciences Raises $5.5 Million In Series B Funding | Miami, Florida based Vigilant Biosciences is a leading high-tech healthcare company that focuses on ... | pulse2.com... |
25.02.2015 | Vigilant Biosciences Closes $5.5M in Series B | MIAMI, FL, Leading innovator and developer of solutions that aid in the early detection and interv... | vcnewsdail... |
24.02.2015 | Vigilant Biosciences Completes $5.5M Series B Funding | Vigilant Biosciences, Inc., a Miami, Florida-based provider of solutions for the early detection and... | finsmes.co... |
26.03.2014 | Rinse-and-spit test kit company gets $2.3M to develop an ear... | The company is developing a low-cost kit for assessing a person’s risk of oral cancer before any les... | medcitynew... |
Show more